advanced glycation end-products on Diabetic Nephropathy

Phase 3

• Conditions: Condition 1: Diabetes. Condition 2: Diabetic nephropathy.; Diabetes mellitus due to underlying condition with kidney complications; Diabetes mellitus due to underlying condition with diabetic nephropathy; E08.2; E08.21

• Registration Number: IRCT20191004044979N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 93

Inclusion Criteria

Willingness to participate in the study
Diabetes diagnosis by a specialist physician (based on criteria of the American Diabetes Association)
Diagnosis of nephropathy by a specialist physician (based on criteria of the American Diabetes Association), patient with a minimum GFR equal to or greater than 30 mL / min / 1.73 m2 and in microalbuminuria (299-30 mg / g Cr) or macroalbuminuria (mg / g Cr) 300=)
No use of alcohol and tobacco
Constant weight during the last 6 months (self-report)
The constancy of the type and dose of drugs in the past 6 months (self-report)

Exclusion Criteria

Occurrence of acute heart disease, stroke, liver or gastrointestinal diseases, thyroid and parathyroid disease, rheumatoid arthritis and infectious
Pregnancy or lactation
Using any dietary supplement in the past 6 months (self-report)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rine microalbumin. Timepoint: At start and after 10 weeks of intervention. Method of measurement: Biochemical (with special kits made by BIOREX company by immunoturbidometric method).;Estimated glomerular filtration rate. Timepoint: Before intervention and 10 weeks after intervention. Method of measurement: The CKD-EPI Creatinine Equation for Glomerular Filtration Rate.